Stocktoria
Adicet Bio, Inc. ACET
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-01-26
Adicet Bio, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M | $34.3M | $23.7M | $14.7M | $16.8M |
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M | -$39.2M | -$31.4M | -$15.0M | -$18.9M |
| Interest expense | $36,000 | $4,000 | $25,000 | $80,000 | $176,000 | $134,000 | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | -$125,000 | -$2.8M | $19,000 | -$589,000 | $0 |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M | -$36.7M | -$28.1M | -$9.3M | -$33.8M |
| EPS (diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | — | — | — | — |
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M | -$41.6M | -$27.9M | -$18.2M | -$11.0M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M | -$42.5M | -$29.0M | -$19.1M | -$11.0M |
| Cash & equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M | $84.3M | $10.6M | $9.5M | $53.3M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M | $153.8M | $81.6M | $109.9M | $55.2M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M | $44.0M | $27.9M | $5.7M | $5.5M |
| Shareholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M | $109.8M | -$60.4M | -$33.5M | -$26.9M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.